Aurobindo Pharma Limited

Aurobindo Pharma Limited

Aurobindo Pharma USA, a wholly-owned subsidiary of Aurobindo Pharma Limited, has received U.S. Federal Trade Commission (FTC) approval to acquire Lannett Company LLC for $250 million. This acquisition, set to close by June 2026, will significantly expand Aurobindo's portfolio of complex generic and non-opioid controlled substances and add a U.S.-based manufacturing facility. The transaction is expected to be immediately accretive to Aurobindo Group's earnings per share and generate meaningful cost efficiencies and synergies, supporting sustainable long-term growth.

Aurobindo Pharma Limited

Aurobindo Pharma Limited announced the completion of a US FDA Pre-Approval Inspection (PAI) at its 100% stepdown subsidiary, Eugia Steriles Private Limited. The inspection, held from June 10 to June 19, 2026, at the facility in Andhra Pradesh, concluded with five observations. The company has stated it will respond to these observations within the stipulated timeframe. This update is significant for investors as a successful resolution of these observations is crucial for securing FDA approvals for new products manufactured at this facility, impacting the company's future revenue potential from the US market.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has announced a disclosure under Regulation 31(4) of the SEBI Takeover Regulations. Promoter K. Nithyananda Reddy, on behalf of the promoter and promoter group, declared that they have not made any new encumbrances (such as pledges) on their shares in the company during the financial year ended March 31, 2026. This declaration confirms that no additional shares were pledged beyond what was already disclosed to the stock exchanges. For investors, this signifies transparency from the promoters regarding their shareholdings, providing reassurance about the stability of their stake.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has announced that it has received the necessary approval from the US Federal Trade Commission (FTC) for its acquisition of the Lannett business. This approval pertains to Aurobindo Pharma USA Inc., a wholly-owned subsidiary, acquiring 100% of the membership interest in Lannett Company LLC. This marks a crucial step forward for the previously announced acquisition. For investors, this signifies the removal of a major regulatory hurdle, paving the way for the completion of the transaction.